Is PTCT or PULM more undervalued in 2026?

CirclFi compares PTC Therapeutics, Inc. (PTCT) and Pulmatrix, Inc. (PULM) using 13 institutional-grade valuation models. PTCT has a Quality of Company score of 4.1/10 while PULM scores 5.6/10.

Which is a better buy — PTCT or PULM?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PTCT and PULM valuations compare?

PTCT at $71.05 and PULM at $1.38 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PTCT vs PULM Valuation Comparison 2026 — Intrinsic Value Analysis

PTCT

Biotechnology

PTC Therapeutics, Inc.

Quality

4.1

out of 10

Value Trap

SAFE

Price

$71.05

Last close

Models

13/13

Active

PULM

Biotechnology

Pulmatrix, Inc.

Quality

5.6

out of 10

Value Trap

SAFE

Price

$1.38

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	PTCT Fair Value	PTCT Upside	PULM Fair Value	PULM Upside
Bayesian DCF	Intrinsic	$25.19	-64.5%	$0.87	-37.1%
Earnings Power Value	Intrinsic	$125.45	+88.5%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$22.29	-66.5%	$3.25	+135.2%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PTCT vs PULM — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PTCT vs PULM — Which Stock Is More Undervalued?

PULM scores higher with a 5.6/10 quality rating vs PTCT's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing PTC Therapeutics, Inc. (PTCT) and Pulmatrix, Inc. (PULM) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PTCT currently trades at $71.05 with a QOC of 4.1/10, while PULM trades at $1.38 with a QOC of 5.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).